yehuda baruch

warning: Creating default object from empty value in /home/hemporg/public_html/news/modules/taxonomy/taxonomy.pages.inc on line 34.

Global: One World Cannabis To Offer Alternative Treatment For Chronic Pain

OneWorldCannabis(logo)

OWC Pharmaceutical Research Corp., an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, announced on Wednesday that it "is offering new and alternative hope to patients diagnosed with chronic pain."

The company's wholly owned subsidiary, One World Cannabis Ltd., has already filed two provisional patent applications with the USPTO related to the development of two unique formulations that include cannabis extracts and a new delivery system to treat fibromyalgia and migraines, and has begun researching and developing new cannabis-based therapies to help alleviate the suffering of patients experiencing enduring pain.

The news comes about after the FDA recently announced to increase existing heart attack and stroke warnings for both over-the-counter and prescription non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs), which are typically used to treat chronic pain. The cannabis-based novel treatment employed by One World Cannabis could be an alternative to NSAIDs to treat long-lasting pain and fever from many different long- and short-term medical conditions.

In addition, the cannabis-based treatment will provide physicians, as well as patients, with the ability to control and administrate optimal dosage, thus offering an alternative to current delivery systems that are not acceptable to scientists and physicians, such as smoking marijuana, edibles and oil extracts with no substantial dosage control, according to OWC.

Israel: Researchers Eliminate 60% of Myeloma Cells With Cannabis-Based Treatments

OneWorldCannabis(logo)

As the possibilities for cannabis-based treatments continue to make headlines in the medical world, One World Cannabis, a medical-cannabis research company, has announced that the initial results of its landmark study on treating multiple myeloma with cannabis-based solutions were extremely promising. After a series of tests using cannabis-based treatments, researchers were able to eradicate 60 percent of multiple myeloma cells.

The disease is one of the most deadly hematologic cancers and individuals diagnosed with the disease often have about a 50 percent survival rate.

OWC Pharmaceutical Research Corp. on Wednesday announced that its wholly owned subsidiary, One World Cannabis Ltd., an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, has received the first basic science study (lab) results on the effect of several combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma cell line RPMI8226.

Based on the results, One World Cannabis will submit the clinical trial protocol to the IRB (Helsinki committee). The company expects to receive institutional review board approval for the study within 6-9 weeks.

The OWC multiple myeloma study was done by three repetitive tests on the effect of cannabis extract with various combination ratios of THC/CBD and pure THC and CBD (50 percent concentration). The results present more than 60 percent malignant cell death. More results of pure THC and CBD are under further analysis.

New York: One World Cannabis Implements Regulatory Services For Medical Marijuana Program

OneWorldCannabis(logo)

Training and Education Infrastructure to Provide "Turnkey Service" to Yield New York Medical Cannabis Patient Communities

OWC Pharmaceutical Research Corp., an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, on Monday announced that its wholly-owned subsidiary, One World Cannabis Ltd., is implementing regulation and patient-care consultancy services in New York to further advance the application and registration of medical cannabis business licenses within the existing medical cannabis program.

"Our intention is to provide support to local New York businesses which intend to dispense and manufacture medical cannabis and help shepherd certifications through the Medical Cannabis Program," said Dr. Yehuda Baruch, One World Cannabis director of research and regulatory affairs and international authority on medical cannabis programs.

In addition to helping guide certified New York-based medical cannabis businesses through the regulatory framework and operating infrastructure, One World Cannabis said it is helping to institute the creation of a medical cannabis patients' center, consisting of patient communities. The company said it is also offering training and educational modules for patients -- as well as physicians, caregivers and researchers -- to enhance the understanding of patient-focused medical cannabis programs within existing and developing U.S. markets.

Syndicate content